|
|
|
|
|
|
|
Array Biopharma Inc (ARRY)
|
|
14.17 0.08 (0.57%)
|
04-23 16:00
|
|
Open:
|
14.15
|
Pre. Close:
|
14.09
|
|
High:
|
14.48
|
Low:
|
14.05
|
|
Volume:
|
1,585,912
|
Market Cap:
|
2942M
|
|
|
|
Stock Price Prediction (Update at 5:00pm est.)
|
|
If
tomorrow:
|
Open
lower
|
Open
higher
|
|
High:
|
14.487 - 14.574
|
14.574 - 14.658
|
|
Low:
|
13.845 - 13.947
|
13.947 - 14.045
|
|
Close:
|
14.014 - 14.164
|
14.164 - 14.307
|
|
|
|
Technical analysis (as of: 2018-04-23 4:27:11 PM)
|
|
Overall:
|
 
|
|
Stoxline posted a SELL today, upgraded from strong sell. But this stock still is very strong for short side. So you may continue to hold short positions or sell your long positions. You are relatively safe to short or sell as long as the BUY warning is not issued.
|
|
Target:
|
Six months: 18.84  One year: 20.35
|
|
Support:
|
Support1: 14.05 Support2: 11.69
|
|
Resistance:
|
Resistance1:
16.13 Resistance2: 17.42
|
|
Pivot:
|
14.99
|
|
Moving Averages:
|
MA(5): 14.70 MA(20): 15.30
MA(100): 14.79 MA(250): 11.60
|
|
MACD:
|
MACD(12,26):
-0.56 Signal(12,26,9): -0.48
|
|
%K %D:
|
%K(14,3): 4.10 %D(3): 16.39
|
|
RSI:
|
RSI(14): 38.09
|
|
52-Week:
|
High: 18.78
Low: 6.73 Change(%): 60.8
|
|
Average Vol(K):
|
3-Month: 324303
10-Days 218012
|
|
|
|
|
|
★
Strong Sell
★★
Sell ★★★
Neutral
★★★★
Buy
★★★★★
Strong Buy
|
|
|
Price, moving averages and
Bollinger Bands
|
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.ARRY has closed above bottom band by 10.6%. Bollinger Bands are 19.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|
|
|
Headline News
|
|
2018-04-17T11:46:21-04:00
JF's Core Biotech Buys #11: Positive News For Several Holdings, A Change To Benchmarks And Introducing Our 17th Position
2018-04-10T01:35:52-04:00
JF's Core Biotech Buys #10: Incyte Disappoints, Optimism Returns To Gene Therapy And A New Position
2018-04-05T06:47:07-04:00
By The Numbers: Best Biotech Stocks
2018-04-03T13:10:52-04:00
JF's Core Biotech Buys #9: Shire In Play, Volatility Continues And Capitalizing On Weakness
2018-03-26T15:30:55-04:00
JF's Core Biotech Buys #8: Taking Advantage Of Volatility And Initiating A Position In Dynavax
2018-03-22T09:00:00-04:00
Array BioPharma Announces Publication of Detailed Phase 3 COLUMBUS Trial Data of Encorafenib and Binimetinib in Melanoma Patients in The Lancet Oncology
2018-03-20T12:01:06-04:00
Biotechs Approaching New Waters
2018-03-20T07:40:36-04:00
JF's Core Biotech Buys Edition 1 Volume 7: Updates And Taking Advantage Of Current Weakness
|
|
|
Financial Analysis
|
|
Growth
|
|
|
Growth measures the growth of both a company's revenue
and net income. it tells investors how fast a company is growing.
|
|
Profitability
|
|
|
Profitability measures a company’s ability to
generate earnings as compared to its expenses
and other relevant costs.
|
|
Solvency
|
|
|
Solvency measures a company's ability to meet its long-term debts.
Acceptable solvency ratios will vary from industry to industry.
|
|
Efficiency
|
|
|
Efficiency measures the strength of a company's return on invested capital.
It can identify business that are better managed or not.
|
|
Click here to get more fundamental analysis.
|
|
